PacBio — Third Quarter 2026 Earnings Summary

PacBio reported third-quarter 2026 total revenue of $40.6 million, driven by demand for instruments and consumables, with 35 new Vega systems delivered. The company highlighted the adoption of its SPRQ-Nx technology, which now accounts for over half of Revio consumables revenue, and announced strategic collaborations with Verily Health and TychoBio to advance AI-driven genomic research. Financial results showed a GAAP net loss of $37.8 million, while non-GAAP net loss was $32.8 million, reflecting restructuring efforts and higher manufacturing costs. PacBio expects full-year 2026 revenue to range between $155 million and $160 million.